| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| ln Vitro |
Morusinol significantly inhibited collagen- and arachidonic acid-induced washed rabbit platelet aggregation in a concentration-dependent manner, with IC50 values of 13.4±5.4 μg/mL for collagen-induced aggregation and 19.8±3.5 μg/mL for arachidonic acid-induced aggregation. The inhibitory effect was not observed for thrombin-induced platelet aggregation, indicating specificity for collagen and arachidonic acid pathways. [1]
Morusinol decreased collagen-induced TXB2 formation by 32.1%, 42.0%, and 99.0% at concentrations of 5, 10, and 30 μg/mL, respectively, compared to the control stimulated by agonist alone. Arachidonic acid-induced TXB2 formation was reduced by 8.0%, 24.1%, and 29.2% at the same respective concentrations. [1] |
|---|---|
| ln Vivo |
Oral administration of Morusinol at 20 mg/kg once daily for three days significantly prolonged the time to arterial occlusion in a ferric chloride (FeCl3)-induced rat carotid artery thrombosis model. The occlusion time was 42.8±4.8 minutes in the Morusinol-treated group, compared to 22.5±2.5 minutes in the control group (1% CMC) and 29.3±1.5 minutes in the aspirin-treated group (20 mg/kg). This suggests that Morusinol exerts a stronger inhibitory effect on arterial thrombus formation than aspirin at the same dosage. [1]
|
| Cell Assay |
Washed rabbit platelets were prepared from blood collected from the ear artery of male New Zealand white rabbits into anticoagulant citrate dextrose (ACD) solution (containing 0.8% citric acid, 2.2% trisodium citrate, and 2% dextrose). Platelet-rich plasma (PRP) was obtained by centrifugation at 230×g for 10 min, and platelets were sedimented by centrifugation of PRP at 800×g for 15 min, then washed with HEPES buffer (137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 5.6 mM glucose, 3.8 mM HEPES, pH 6.5) containing 0.35% BSA and 0.4 mM EGTA. The washed platelets were resuspended in HEPES buffer (pH 7.4) to a final concentration of 4×10^8 cells/mL. Platelet aggregation was measured with an aggregometer using the turbidimetric method. The washed platelet suspension was incubated at 37°C with stirring at 1,000 rpm, then various concentrations of Morusinol (5–30 μM) were added. After 3 min preincubation, platelet aggregation was induced by addition of collagen (10 μg/mL), arachidonic acid (100 μM), or thrombin (0.05 U/mL). The extent of platelet aggregation was expressed as a percentage of the control value stimulated by an agonist alone. [1]
|
| Animal Protocol |
Male Sprague-Dawley rats (250–300 g) were used. Morusinol (20 mg/kg) or aspirin (20 mg/kg, positive control) was administered orally once daily for three days. The control group received 1% carboxymethyl cellulose (CMC). Rats were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and maintained at 37°C on a servo-controlled heated operating table. A segment of the right carotid artery was isolated and dissected free from the vagus nerve and surrounding tissues. Aortic blood flow was monitored with a blood flowmeter. Arterial thrombus formation was induced by wrapping a 2 mm² piece of filter paper saturated with 50% ferric chloride (FeCl3) in distilled water around the carotid artery near the flowmeter probe for 10 minutes. The time required for thrombotic arterial occlusion was measured for up to 60 minutes; vessels that did not occlude within 60 minutes were assigned an occlusion time of 60 minutes. [1]
|
| References | |
| Additional Infomation |
Morusinol is a type of flavonoid compound. It has been reported to exist in mulberry trees (Morus lhou), Mongolian mulberry (Morus mongolica), and other organisms with relevant data.
Morusinol is an isoprenoid flavone isolated from Morus alba root bark. The study suggests that its antiplatelet mechanism may involve inhibition of collagen- and arachidonic acid-induced intracellular calcium mobilization and arachidonic acid metabolites, including TXA2, prostaglandin, and eicosanoids. However, this potential mechanism was not proven in the study. Morusinol may have therapeutic potential for cardiovascular diseases such as transient ischemic attacks or stroke via modulation of platelet activation. The chemical structure of Morusinol was confirmed by 1H-NMR, 13C-NMR, and ESI-MS (m/z 437 [M-H]⁻). [1] |
| Molecular Formula |
C25H26O7
|
|---|---|
| Molecular Weight |
438.4697
|
| Exact Mass |
438.167
|
| CAS # |
62949-93-3
|
| PubChem CID |
5481968
|
| Appearance |
Light yellow to yellow solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
699.6±55.0 °C at 760 mmHg
|
| Melting Point |
215 - 216 °C
|
| Flash Point |
240.9±25.0 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.637
|
| LogP |
4.61
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
32
|
| Complexity |
798
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C2C([H])=C(C3C(C(=C(C4C([H])=C([H])C(=C([H])C=4O[H])O[H])OC=3C=2C([H])=C([H])C1(C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])O[H])=O)O[H]
|
| InChi Key |
AFOKZNPZDXHDHD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H26O7/c1-24(2,30)9-7-16-21(29)20-18(28)12-19-15(8-10-25(3,4)32-19)23(20)31-22(16)14-6-5-13(26)11-17(14)27/h5-6,8,10-12,26-28,30H,7,9H2,1-4H3
|
| Chemical Name |
2-(2,4-dihydroxyphenyl)-5-hydroxy-3-(3-hydroxy-3-methylbutyl)-8,8-dimethylpyrano[2,3-h]chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2807 mL | 11.4033 mL | 22.8066 mL | |
| 5 mM | 0.4561 mL | 2.2807 mL | 4.5613 mL | |
| 10 mM | 0.2281 mL | 1.1403 mL | 2.2807 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
